SeaStar Medical Holding Corporation
ICUSeaStar Medical Holding Corporation in brief
SeaStar Medical Holding Corporation is a listed company in the Shell Companies industry, based in Denver, Colorado, USA. Its market value was $12 M on 30 October 2026, which makes it the 25,517th largest listed company in the world and the 4,255th largest in the USA on this site. In the year to December 2025 it had sales of $1 M and a net loss of $12 M. It employs about 17 people and Eric Schlorff is its chief executive. Its largest product and service lines by sales in 2025 were Pediatric SCDs (97%). Its shares trade under the symbol ICU (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About SeaStar Medical Holding Corporation
We are a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. Our Selective Cytopheretic Device is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. It has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases.
We received Food and Drug Administration approval on February 21, 2024, under a Humanitarian Device Exemption for our pediatric SCD therapy. It is the only FDA approved product for use in pediatric patients with acute kidney injury due to sepsis or a septic condition requiring kidney replacement therapy. We shipped our first commercial pediatric SCD in July 2024. In addition, we are currently conducting a pivotal clinical trial, also referred to as "NEUTRALIZE-AKI" to assess the safety and efficacy of the SCD therapy in critically ill adult patients with AKI requiring continuous renal replacement therapy. We are also conducting a feasibility study of the SCD therapy in adult patients with Cardiorenal Syndrome awaiting left ventricular assist device implantation.
From the company's annual report filed with the US SEC: read the report
SeaStar Medical Holding Corporation timeline
- 2020
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2021
- 🔔· approximateInitial public offering on Nasdaq
- 🔔Initial public offering as LMF Acquisition Opportunities IncFinal prospectus filed with the SEC on 27 January 2021; shares registered for exchange trading on 22 January 2021. The blank-check company later merged with the business that carries the name today.
- 2022
- ✎Renamed SeaStar Medical Holding CorpFormerly LMF Acquisition Opportunities Inc.
Events of SeaStar Medical Holding Corporation from SEC EDGAR and the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,762 (Dec 2022) · #5,458 (Jul 2023) · #4,334 (Jan 2024) · #2,390 (Mar 2026) · #3,998 (Aug 2026) · #4,127 (Oct 2026) · #4,256 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 5.6×
- Price / book
- 1.2×
- Free cash flow yield
- —
- Net margin (TTM)
- -673.9%
- Operating margin
- -990.2%
- Return on equity
- -141.0%
- Liabilities / assets
- 26.4%
- Net debt
- $4M
- Revenue growth
- +778.6%
- R&D / revenue
- 611.4%
- Revenue per employee
- $72 K
- Profit per employee
- $-715 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1M | +778.6% | $-12M | $-12M | -987.8% |
| Dec 2024 | $0M | — | $-18M | $-25M | -17735.7% |
| Dec 2023 | — | — | $-14M | $-26M | — |
| Dec 2022 | — | — | $-12M | $-12M | — |
| Dec 2021 | — | — | $-4M | $-5M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-14M | — | — | — | — |
| Dec 2024 | $-16M | — | — | $-6.63 | — |
| Dec 2023 | $-10M | — | — | $-30.26 | — |
| Dec 2022 | $-8M | — | — | $-1.48 | — |
| Dec 2021 | $-5M | — | — | $-0.63 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $1M (+255.6% on a year earlier), net income $-5M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Nov 3, 20268-KCurrent reportOther events
- Oct 5, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Other events
- Aug 12, 202610-QQuarterly report · period to Jun 2026
- Aug 12, 20268-KCurrent reportResults of operations
- Jul 1, 20268-KCurrent reportDirectors or officers changed
- Jun 23, 20268-K/ACurrent report (amended)Directors or officers changed
- Jun 17, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- May 13, 202610-QQuarterly report · period to Mar 2026
- May 13, 20268-KCurrent reportResults of operations
- May 7, 2026S-1/AIPO registration (amended)
Official filings of SeaStar Medical Holding Corporation with the US Securities and Exchange Commission.
Annual results
- Revenue
- $1 M
- Operating income
- $-12 M
- Net income
- $-12 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $14 M
- Total liabilities
- $4 M
- Total equity
- $10 M
As of December-2025
Top 21 institutional investors in SeaStar Medical Holding Corporation#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | LPL Financial LLC | 66,801 | New | 1.26% | $0 M | Nov 6, 2026 |
| 2 | Geode Capital Management, LLC | 51,009 | +1,416 (+2.86%) | 0.96% | $0 M | Nov 6, 2026 |
| 3 | Vanguard Capital Management LLC | 33,091 | 0 (0.00%) | 0.62% | $0 M | Nov 13, 2026 |
| 4 | UBS Group AG | 26,614 | -4,784 (-15.24%) | 0.50% | $0 M | Nov 10, 2026 |
| 5 | Vanguard Fiduciary Trust Co | 13,692 | 0 (0.00%) | 0.26% | $0 M | Nov 13, 2026 |
| 6 | HRT Financial LP | 12,579 | New | 0.24% | $0 M | Nov 13, 2026 |
| 7 | Northern Trust Corp | 10,402 | 0 (0.00%) | 0.20% | $0 M | Nov 16, 2026 |
| 8 | PNC Financial Services Group, Inc. | 4,943 | 0 (0.00%) | 0.09% | $0 M | Nov 6, 2026 |
| 9 | BlackRock, Inc. | 913 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 10 | Barclays PLC | 633 | +629 (+15725.00%) | 0.01% | $0 M | Nov 6, 2026 |
| 11 | Tower Research Capital LLC (TRC) | 565 | -791 (-58.33%) | 0.01% | $0 M | Nov 16, 2026 |
| 12 | Osaic Holdings, Inc. | 195 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 13 | NewEdge Advisors, LLC | 176 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 14 | Vanguard Global Advisers, LLC | 165 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 15 | Fifth Third Bancorp | 50 | New | 0.00% | $0 M | Nov 5, 2026 |
| 16 | TD Waterhouse Canada Inc. | 22 | 0 (0.00%) | 0.00% | $0 M | Oct 16, 2026 |
| 17 | SBI Securities Co., Ltd. | 14 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 18 | SOA Wealth Advisors, LLC. | 6 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 19 | Wells Fargo & Company/mn | 4 | New | 0.00% | $0 M | Nov 16, 2026 |
| 20 | Caitong International Asset Management Co., Ltd | 4 | +2 (+100.00%) | 0.00% | $0 M | Oct 29, 2026 |
| 21 | HighMark Wealth Management LLC | 2 | 0 (0.00%) | 0.00% | $0 M | Nov 17, 2026 |
Mutual funds holding SeaStar Medical Holding Corporation#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 33,091 | $0 M | 0.62% | <0.01% | +39% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 21,929 | $0 M | 0.41% | <0.01% | −1.4% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 8,656 | $0 M | 0.16% | <0.01% | +291% | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 5,814 | $0 M | 0.11% | <0.01% | +46% | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 2,835 | $0 M | 0.05% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 447 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 6 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at SeaStar Medical Holding Corporation#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Kevin ChungChief Medical Officer | Buy | +7,800 | $0.845 | $7 K | 35,821 | Form 4 |
| filed | Michael MessingerChief Financial Officer | Buy | +2,500 | $0.850 | $2 K | 5,000 | Form 4 |
| filed | Michael MessingerChief Financial Officer | Buy | +750 | $3.270 | $2 K | 2,500 | Form 4 |
| filed | Kevin ChungChief Medical Officer | Grant or award | +7,202 | — | — | 28,021 | Form 4 |
| filed | Bernadette N. VincentDirector | Grant or award | +4,000 | — | — | 8,200 | Form 4 |
| filed | Kenneth Van HeelDirector | Grant or award | +4,000 | — | — | 11,940 | Form 4 |
| filed | Eric SchlorffChief Executive Officer | Grant or award | +10,288 | — | — | 50,140 | Form 4 |
| filed | Jennifer A. BairdDirector | Grant or award | +4,000 | — | — | 10,620 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: SeaStar Medical Holding Corporation#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-25 reverse split
Trading halts
- 2026-01-03 00:50 UTC, code T3, resumed 14:00 UTC
Fails to deliver
- : 243 shares at $2.31
- : 2,592 shares at $3.06
- : 44,694 shares at $3.49
- : 151,970 shares at $3.72
- : 30,068 shares at $3.19
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
SeaStar Medical Holding Corporation scorecard#
Passes 4 of the 12 checks that could be worked out: strongest in valuation (2 of 4), weakest in profitability (0 of 4). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation2 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.2×Price to book 1.2× against Shell Companies's median of 2.0×.
- ✓Price to sales below its peers' median5.6×Price to sales 5.6× against Shell Companies's median of 5.7×.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 1
- ✓Revenue grew in the newest year778.6%Revenue up 778.6% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 4
- ✗Profitable in the newest year-$12 MNet income -$12 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-990.2%-990.2% against Shell Companies's median of -141.8% (5 companies).
- ✗Return on equity above 15%-294.9%-294.9% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities3.6×Current ratio 3.63 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-14.95Z-score -14.95 (distress zone) for fiscal 2025.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Shell Companies, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from SeaStar Medical Holding Corporation's statements, beside the median of Shell Companies.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -990.2% | -141.8% | |
| Net margin | -987.8% | -90.5% | |
| Return on equity | -294.9% | -29.6% | |
| Revenue growth | 778.6% | 12.6% |
3of 8on the Piotroski tests of financial strength
- Net loss of $12 million, the 5th loss-making year in a row.
SeaStar Medical Holding Corporation: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 1.2+814%100% | 0.1—100% | 0—— | — | — | |
| Cost of revenue | 0.1—4.3% | 0—0.0% | 0—— | — | — | |
| Gross profit | 1.2+775%95.7% | 0.1—100% | 0—— | — | — | |
| Research and development | 7.5−17.4%609% | 9.1+52.4%6744% | 6.0+139%— | 2.5r2.8−9.5%— | 2.8—— | |
| General and administrative | 5.8−34.2%473% | 8.9+7.7%6572% | 8.2+19.1%— | 6.9r6.6+311%— | 1.7r1.1—— | |
| Operating expenses | 13−25.7%1082% | 18+26.5%13316% | 14+22.4%— | 12+161%— | 4.4—— | |
| Operating income | −12—−987% | −18—−13216% | −14—— | −12—— | −4.4r−1.1—— | |
| Interest and finance income | 0.3+222%26.3% | 0.1—74.8% | 0—— | — | 0.0—— | |
| Interest expense and finance costs | 0.0−87.3%2.5% | 0.2−77.4%181% | 1.1+71.6%— | 0.6+197%— | 0.2—— | |
| Other non-operating income (expense) | 0.0—2.3% | −7.0—−5174% | −12—— | −0.6r−11—— | −0.1—— | |
| Income before tax | −12—−984% | −25—−18390% | −26—— | −12r−23—— | −4.6—— | |
| Income tax | 0.00.0%0.2% | 0.0—2.2% | 0−100%— | 0.0—— | −0.0—— | |
| Net income including minority interests | — | −25—−18393% | −26—— | −12r−23—— | −4.6r0.1—— | |
| Net income attributable to shareholders | −12—−985% | −25—−18393% | −26—— | −12r−23—— | −4.6r0.1—— | |
| Earnings per share, basic | -5.86—— | -66.33r-6.63—— | -30.26r-1.21—— | -1.48r-2.80—— | -0.63—— | |
| Earnings per share, diluted | — | -6.63—— | -30.26r-1.21—— | -1.48r-2.80—— | -0.63—— | |
| Shares, weighted average (basic) | 2.1+454%— | 0.4r3.7−56.8%— | 0.9r22−89.4%— | 8.2+13.4%— | 7.2—— | |
| Shares, weighted average (diluted) | — | 3.7+332%— | 0.9r22−89.4%— | 8.2+13.4%— | 7.2—— | |
| Balance sheet | ||||||
| Cash and cash equivalents | 12+559%84.6% | 1.8+934%39.1% | 0.2+274%5.0% | 0.0−8.9%1.5% | 0.1—8.6% | |
| Receivables | 0.2+112%1.7% | 0.1—2.4% | 0—0.0% | — | — | |
| Inventory | 0.1—0.5% | 0—0.0% | — | — | — | |
| Current assets | 14+261%95.9% | 3.8+63.2%80.9% | 2.3+51.9%65.7% | 1.5r3.0+153%50.0% | 0.6r106—99.7% | |
| Total assets | 14+204%100% | 4.7+32.6%100% | 3.5+15.6%100% | 3.0r4.8+404%100% | 0.6r106—100% | |
| Accounts payable | 0.9−68.9%6.7% | 3.0−30.3%65.4% | 4.4+127%124% | 1.9+2167%63.4% | 0.1r0.4—14.1% | |
| Debt due within a year | — | 0.6+1.6%12.3% | 0.6−52.0%16.1% | 1.2—38.8% | — | |
| Current liabilities | 3.7−45.3%26.4% | 6.8−47.6%147% | 13−19.2%371% | 16r5.4+418%532% | 3.1r0.4—517% | |
| Total liabilities | 3.7−45.3%26.4% | 6.8−60.6%147% | 17−27.0%495% | 24r13+596%783% | 3.4r11—567% | |
| Retained earnings | −152—−1072% | −140—−2996% | −115—−3266% | −89r−99—−2913% | −76r−11—−12655% | |
| Shareholders' equity | 10—73.6% | −2.2—−46.9% | −14—−395% | −21r−8.2—−683% | −2.8r−11—−467% | |
| Total liabilities and equity | 14+204%100% | 4.7+32.6%100% | 3.5+15.6%100% | 3.0r4.8+404%100% | 0.6r106—100% | |
| Shares outstanding | 3.8+491%— | 0.7r6.0−67.7%— | 2.0r48−84.1%— | 13—— | — | |
| Cash-flow statement | ||||||
| Share-based compensation | 0.6−29.7%50.6% | 0.9−54.0%657% | 1.9+47.2%— | 1.3+9264%— | 0.0—— | |
| Cash from operating activities | −14—−1102% | −16—−11857% | −10—— | −7.8—— | −5.1r−1.2—— | |
| Cash from investing activities | — | — | — | — | −106—— | |
| Debt issued | — | 1.1—805% | — | — | — | |
| Shares issued | 16−7.5%1307% | 17+268%12919% | 4.7—— | 0—— | — | |
| Cash from financing activities | 24+34.6%1925% | 18+69.5%13074% | 10+42.1%— | 7.3+160%— | 2.8r107—— | |
| Change in cash | 10+518%823% | 1.6—1217% | — | — | — | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 2.2+146%100% | 0.6+247%100% | 0.6+82.0%100% | 0.5+68.9%100% | 0.4*+527%100% | 0.2+169%100% | 0.3—100% | 0.3—100% | 0.1*—100% | 0.1—100% | 0—— | 0—— | 0*—— | |
| Cost of revenue | 0.2+290%7.4% | 0.0+243%7.6% | 0.1+100%8.8% | 0.0—9.3% | 0.0*—2.9% | 0.0—7.7% | 0.0—8.0% | 0—0.0% | 0*—0.0% | 0—0.0% | 0—— | 0—— | 0*—— | |
| Gross profit | 2.0+139%92.6% | 0.6+247%92.4% | 0.6+80.4%91.2% | 0.4+53.2%90.7% | 0.4*+509%97.1% | 0.2+149%92.3% | 0.3—92.0% | 0.3—100% | 0.1*—100% | 0.1—100% | 0—— | 0—— | — | |
| Research and development | 11+32.1%491% | 3.6+93.2%563% | 2.5+143%410% | 2.3−3.6%474% | 2.2*−19.6%524% | 1.9−20.8%1011% | 1.0−55.6%307% | 2.4+43.3%830% | 2.7*+133%4087% | 2.3—3435% | 2.3—— | 1.7—— | 1.2*—— | |
| General and administrative | 6.4−5.2%294% | 1.6−16.0%251% | 1.8+77.9%298% | 1.7+1.4%345% | 1.2*−41.6%291% | 1.9−13.3%1037% | 1.0−55.9%305% | 1.7−25.3%575% | 2.1*+19.0%3128% | 2.2—3218% | 2.3—— | 2.3—— | 1.8*—— | |
| Operating expenses | 17+15.1%785% | 5.2+37.9%814% | 4.4+111%708% | 4.1−1.5%819% | 3.4*−29.2%815% | 3.7−17.2%2048% | 2.1−55.7%612% | 4.1+4.2%1404% | 4.8*+64.6%7215% | 4.5—6653% | 4.7—— | 4.0—— | 2.9*—— | |
| Operating income | −15—−692% | −4.6—−721% | −3.8—−616% | −3.6—−728% | −3.0*—−718% | −3.6—−1956% | −1.8—−520% | −3.8—−1304% | −4.8*—−7115% | −4.5—−6553% | −4.7—— | −4.0—— | −2.9*—— | |
| Interest and finance income | 0.3+54.8%15.7% | 0.1−49.5%8.5% | 0.1+53.3%11.2% | 0.1+89.6%18.4% | 0.1*+558%29.8% | 0.1+84.5%58.5% | 0.0+80.0%13.3% | 0.0—16.4% | 0.0*—28.4% | 0.1—85.3% | 0.0—— | 0—— | 0*—— | |
| Interest expense and finance costs | 0.0—1.3% | 0.0—0.3% | 0.0−11.1%1.3% | 0.0−45.5%1.2% | 0.0*—3.1% | 0−100%0.0% | 0.0−89.0%2.7% | 0.0−92.3%3.8% | — | 0.3—400% | 0.1—— | 0.1—— | 0.2r2.0*—— | |
| Other non-operating income (expense) | 0.3+18.3%14.3% | 0.1−51.4%8.2% | 0.1—9.9% | 0.1+60.4%17.2% | 0.1*−67.8%26.7% | 0.1—58.5% | −0.2−117%−72.8% | 0.1—18.1% | 0.3*—519% | −0.0—−32.4% | 1.4—— | −8.7—— | −6.5*—— | |
| Income before tax | −15—−678% | −4.5—−713% | −3.7—−607% | −3.5—−711% | −2.9*—−691% | −3.5—−1897% | −2.0—−592% | −3.8—−1286% | −4.4*—−6596% | −4.5—−6585% | −3.2—— | −13—— | −9.5*—— | |
| Income tax | 0.00.0%0.1% | 0—0.0% | 0—0.0% | 0.00.0%0.6% | 0*—0.0% | 0—0.0% | 0−100%0.0% | 0.0—1.0% | 0*—0.0% | 0—0.0% | 0.0—— | 0—— | −0.0*—— | |
| Net income including minority interests | — | — | — | — | — | — | −2.0—−592% | −3.8—−1287% | −4.4*—−6596% | −4.5—−6585% | −3.2—— | −13—— | −9.5*—— | |
| Net income attributable to shareholders | −15—−678% | −4.5—−713% | −3.7—−607% | −3.5—−711% | −2.9*—−691% | −3.5—−1897% | −2.0—−592% | −3.8—−1287% | −4.4*—−6596% | −4.5—−6585% | −3.2—— | −13—— | −9.5r−9.9*—— | |
| Earnings per share, basic | — | -1.03—— | -0.91—— | -0.90—— | — | -1.30r-0.13—— | -1.77r-0.18—— | -4.38r-0.44—— | — | -1.10—— | -1.03—— | -4.73r-0.19—— | — | |
| Earnings per share, diluted | — | — | — | — | — | — | -0.18—— | -0.44—— | — | -1.10—— | -1.03—— | -4.73r-0.19—— | — | |
| Shares, weighted average (basic) | 4.4+64.5%— | 4.4+64.5%— | 4.1+260%— | 3.9+355%— | — | 2.7r26−34.7%— | 1.1r11−64.1%— | 0.9r8.6−67.9%— | — | 4.1—— | 3.2—— | 2.7r67—— | — | |
| Shares, weighted average (diluted) | — | — | — | — | — | — | 11+259%— | 8.6+221%— | — | 4.1—— | 3.2—— | 2.7r67—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 4.0—75.1% | 4.0−71.0%75.1% | 7.0+10.4%80.5% | 9.3+76.5%83.0% | 12+559%84.6% | 14+561%88.6% | 6.3+435%75.2% | 5.3+5.5%37.3% | 1.8+934%39.1% | 2.1—45.4% | 1.2—34.0% | 5.0—64.8% | 0.2—5.0% | |
| Receivables | 0.2—3.4% | 0.2−19.5%3.4% | 0.2−4.1%2.4% | 0.2+62.7%1.6% | 0.2+112%1.7% | 0.2+225%1.4% | 0.2—2.6% | 0.1—0.8% | 0.1—2.4% | 0.1—1.5% | — | — | 0—0.0% | |
| Inventory | 0.0—0.8% | 0.0−45.8%0.8% | 0.10.0%0.9% | 0.1+29.5%0.5% | 0.1—0.5% | 0.1—0.5% | 0.1—0.9% | 0.0—0.3% | 0—0.0% | 0—0.0% | — | — | — | |
| Current assets | 5.0—93.5% | 5.0−66.6%93.5% | 8.2+7.6%95.1% | 11+58.7%95.6% | 14+261%95.9% | 15+311%95.8% | 7.6+217%91.2% | 6.8+3.8%47.8% | 3.8+63.2%80.9% | 3.6—78.8% | 2.4—69.6% | 6.5—84.5% | 2.3—65.7% | |
| Total assets | 5.3—100% | 5.3−65.8%100% | 8.6+3.2%100% | 11−20.7%100% | 14+204%100% | 16+239%100% | 8.4+142%100% | 14r7.6+83.5%100% | 4.7+32.6%100% | 4.6—100% | 3.5—100% | 7.7—100% | 3.5—100% | |
| Accounts payable | 1.5—27.6% | 1.5−27.3%27.6% | 0.8−76.3%8.7% | 0.7−78.8%6.4% | 0.9−68.9%6.7% | 2.0−45.3%13.0% | 3.2−23.3%37.7% | 3.4−12.4%23.9% | 3.0−30.3%65.4% | 3.7—80.4% | 4.1—119% | 3.9—50.1% | 4.4—124% | |
| Debt due within a year | — | — | — | — | — | — | — | — | 0.6+1.6%12.3% | — | — | — | 0.6—16.1% | |
| Current liabilities | 4.8—91.2% | 4.8+19.1%91.2% | 4.4−13.7%50.3% | 3.9−43.9%35.1% | 3.7−45.3%26.4% | 4.1−38.7%26.2% | 5.0−49.2%60.1% | 7.0−27.1%49.5% | 6.8−47.6%147% | 6.6—145% | 9.9—286% | 9.6—125% | 13—371% | |
| Total liabilities | 4.8—91.2% | 4.8+19.1%91.2% | 4.4−13.7%50.3% | 3.9−43.9%35.1% | 3.7−45.3%26.4% | 4.1−38.7%26.2% | 5.0−51.4%60.1% | 7.0−42.4%49.5% | 6.8−60.6%147% | 6.6—145% | 10—299% | 12—158% | 17—495% | |
| Retained earnings | −163—−3079% | −163—−3079% | −159—−1838% | −155—−1378% | −152—−1072% | −149—−958% | −145—−1734% | −143—−1009% | −140—−2996% | −135—−2947% | −131—−3769% | −127—−1646% | −115—−3266% | |
| Shareholders' equity | 0.5—8.8% | 0.5−95.9%8.8% | 4.3+28.6%49.7% | 7.3+1195%64.9% | 10—73.6% | 11—73.8% | 3.3—39.9% | 0.6—4.0% | −2.2—−46.9% | −0.0r−2.1—−0.0% | −6.9—−199% | −4.5r−4.5—−57.8% | −14—−395% | |
| Total liabilities and equity | 5.3—100% | 5.3−65.8%100% | 8.6+3.2%100% | 11+48.3%100% | 14+204%100% | 16+239%100% | 8.4+142%100% | 7.6−1.8%53.5% | 4.7+32.6%100% | 4.6—100% | 3.5—100% | 7.7—100% | 3.5—100% | |
| Shares outstanding | 4.5—— | 4.5−86.9%— | 4.3−75.4%— | 4.0−56.9%— | 3.8+491%— | 34+709%— | 17+811%— | 9.3−87.7%— | 0.7r6.0−67.7%— | 4.2—— | 1.9—— | 75—— | 2.0r48—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 0.2−70.6%10.4% | 0.2−43.8%25.7% | −0.1−202%−16.1% | 0.1−45.5%18.4% | 0.1*−67.0%16.7% | 0.3+45.0%158% | 0.1+137%28.7% | 0.2−61.5%57.0% | 0.2*−45.1%316% | 0.2—294% | 0.0—— | 0.4—— | 0.4*—— | |
| Cash from operating activities | −13—−611% | −3.4*—−531% | −3.0*—−487% | −2.8—−558% | −4.1*—−975% | −3.8*—−2101% | −3.0*—−890% | −2.7—−906% | −4.7*—−7004% | −5.0*—−7356% | −2.8*—— | −3.5—— | −4.5*—— | |
| Debt issued | — | — | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | 0*—— | 1.1—— | — | |
| Shares issued | 3.5−80.9%160% | 0.5*−94.1%84.9% | 0.8*−77.4%132% | 0.3−79.0%66.5% | 1.8*−53.6%426% | 9.2*+1.0%5018% | 3.6*—1062% | 1.6−65.5%534% | 3.9*+11.6%5760% | 9.1*—13368% | −0.1*—— | 4.5—— | 3.5*—— | |
| Cash from financing activities | 3.4−86.7%159% | 0.4*−96.4%63.5% | 0.6*−84.9%98.4% | 0.1−97.9%26.1% | 2.3*−47.8%550% | 11*+91.4%6178% | 4.0*—1187% | 6.1−26.4%2092% | 4.4*−3.4%6612% | 5.9*—8684% | −1.0*—— | 8.3—— | 4.6*—— | |
| Change in cash | −9.8−184%−451% | −3.0*−140%−468% | −2.4*−337%−388% | −2.6−176%−532% | −1.8*—−425% | 7.5*—4077% | 1.0*—298% | 3.5—1187% | −0.3*—−393% | — | — | — | — | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What SeaStar Medical Holding Corporation sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Pediatric SCDs$1 M97%+1100%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Events at SeaStar Medical Holding Corporation#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Delisting notice 2 · Acquisition or sale completed 1 · Directors and officers 7 · Material agreement 3 · Unregistered share sale 3 · Shareholder rights changed 2 · Shareholder vote 3 · Results announced 6
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K/A | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder rights changed | 8-K/A | |
| Shareholder rights changedShareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K/A | |
| Acquisition or sale completed | 8-K | |
| Delisting notice | 8-K | |
| Delisting notice | 8-K/A | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Shareholder vote | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How SeaStar Medical Holding Corporation compares in Shell Companies
- Market cap$12 M · higher than 15% of 61
- Revenue$1 M · higher than 72% of 59
- Net margin-673.9% · higher than 6% of 17
- Revenue growth778.6% · higher than 90% of 22
- Price / sales5.6× · lower than 47% of 16
- Price / book1.2× · lower than 54% of 14
Peer comparison · Shell Companies
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| SeaStar Medical Holding Corporation🇺🇸 | $12 M | — | -673.9% | +778.6% |
| Oklo Inc.🇺🇸 | $5.2 B | — | — | — |
| Core Scientific Inc.🇺🇸 | $4.6 B | — | -18.3% | -37.5% |
| 2MX Organic S.A.🇫🇷 | $1.3 B | — | — | — |
| Corner Growth Acquisition Corp. 2🇺🇸 | $721 M | 450.6× | — | — |
| Sable Offshore Corp.🇺🇸 | $599 M | — | — | — |
| Solid Power, Inc.🇺🇸 | $456 M | — | -429.5% | +8.0% |
| Orchestra BioMed Holdings, Inc.🇺🇸 | $444 M | — | -182.5% | +1168.2% |
| M3-Brigade Acquisition ii Corp.🇺🇸 | $442 M | — | — | — |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at SeaStar Medical Holding Corporation? Verify and update this profile — free
Show SeaStar Medical Holding Corporation's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.